Guanen Zhou

Guanen Zhou

Auto-generated profile, based on publicly available information

Guanen Zhou

Department of Neurology, Tianjin Huanhu Hospital, Tianjin University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2016 in BMC Neurology
Verified
Journal Article
Open access
PDF file
WZWenjuan Zhao
Wenjuan Zhao
ZAZhongping An
Zhongping An
YHYan Hong
Yan Hong
GZGuanen Zhou
Guanen Zhou
JGJingjing Guo
Jingjing Guo
JWJinghua Wang
Jinghua Wang
Total cholesterol is a well-documented risk factor for coronary disease. Previous studies have shown that high total cholesterol level is associated with better stroke outcomes, but the association of low total cholesterol levels and ischemic stroke outcomes is rare. Therefore, we aimed to assess the association of low total cholesterol levels and stroke outcomes among acute ischemic stroke patients in China. This study recruited 6407 atherothrombotic infarction patients from Tianjin, China, between May 2005 and September 2014. All patients were categorized into five groups according to TC level quintiles at admission. Differences in subtypes, severity, risk factors, and outcomes at 3, 12, and 36 months after stroke were compared between these groups. In total, 1256 (19.6 %) patients had low cholesterol levels, with a higher prevalence in men than in women (23.7 % vs. 11.2 %, P < 0.001). Compared with higher cholesterol levels, the lowest cholesterol level quintile (TC, <4.07 mmol/L) was associated with older age (64.7 years, P = 0.033), anterior circulation infarct (22.8 %), atrial fibrillation (4.9 %), current smoking (41.1 %), and alcohol consumption (21.1 %) and lower frequencies of hypertension (72.9 %), diabetes (30.7 %), and obesity (9.9 %). Dependency and recurrence rates were significantly higher at 36 months in patients in the lowest TC level quintile than in those with higher cholesterol levels (dependency rates, 51.2 % vs 45.2 %; P = 0.007 and recurrence rates, 46.3 % vs 37.3 %, P = 0.001). Moreover, these differences remained after adjustment for age, sex, stroke severity, and Oxfordshire Community Stroke Project classification (odds ratios [ORs] for dependency rate, 1.41; 95 % confidence interval [CI], 1.11, 1.79; P = 0.005 and recurrence rate, 1.50; 95 % CI, 1.19, 1.89; P = 0.001). However, mortality rates after stroke were not significantly different between the groups. These findings suggest that statin treatment for patients with atherothrombotic infarction and low cholesterol levels increase long-term dependency and recurrence rates, but do not increase mortality rates. It is crucial to highlight the different impact of statin treatment on patients with atherothrombotic infarction and lower cholesterol levels for secondary stroke prevention in China.

4 September 2018 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
JLJi Liu
Ji Liu
GZGuanen Zhou
Guanen Zhou
BKBradley J Kolls
Bradley J Kolls
YTYanli Tan
Yanli Tan
CFChuan Fang
Chuan Fang
DLDaniel Laskowitz
Daniel Laskowitz
Objective Subarachnoid haemorrhage (SAH) accounts for 3% of all strokes, and is associated with significant morbidity and mortality. There is growing evidence implicating apolipoprotein E (apoE) in mediating adaptive anti-inflammatory and neuroprotective responses following ischaemic and traumatic brain injury. In the current study, we test the efficacy of a small apoE mimetic peptide, CN-105 in a murine model of SAH. Methods Mice subjected to SAH received repeated intravenous injections of CN-105 every 12 hours for 3 days, with the first dose given 2 hours after injury. Daily functional outcomes were assessed by rotarod and neurological severity score. Haemorrhage grade and cerebral vascular diameters were measured at 5 days post-SAH. Cerebral microgliosis, neuronal degeneration and survival were analysed at 5 and 35 days post-SAH, respectively. Results CN-105 reduces histological evidence of inflammation, reduces vasospasm and neuronal injury and is associated with improved long-term behavioural outcomes in a murine model of SAH. Conclusions Given its favourable pharmacokinetic profile, central nervous system penetration and demonstration of clinical safety, CN-105 represents an attractive therapeutic candidate for treatment of brain injury associated with SAH.

1 February 2021 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
QLQian Liu
Qian Liu
WZWenjuan Zhao
Wenjuan Zhao
YXYonghong Xing
Yonghong Xing
YHYan Hong
Yan Hong
GZGuanen Zhou
Guanen Zhou

11 December 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XZXuan Zou
Xuan Zou
XJXi-Yue Jing
Xi-Yue Jing
GZGuan-En Zhou
Guan-En Zhou
Objective: This study aims to identify the risk factors for central hypoventilation in patients with anti- N -methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Methods: Patients with anti-NMDAR encephalitis who were hospitalized between January 2020 and January 2025 were identified from the Tianjin Huanhu Hospital database, affiliated with Tianjin University. Patients were categorized into a central hypoventilation group and a non-central hypoventilation group, and potential risk factors were collected. Statistical methods were used to compare the two groups and identify risk factors. Results: The analysis revealed that the central hypoventilation group exhibited a higher incidence of involuntary movements ( χ² =5.662, P =0.017), lower admission Glasgow Coma Scale (GCS) scores ( Z =-3.749, P <0.001), and higher cerebrospinal fluid (CSF) antibody titers compared with the non-hypoventilation group ( Z =-3.344, P =0.001). Multivariate logistic regression analysis identified only admission GCS score and CSF antibody titer as independent risk factors. A lower GCS score [ P =0.018; OR ( 95% CI ): 0.556 (0.343, 0.903)] and a higher CSF antibody titer [ P =0.048; OR ( 95% CI ): <0.001 (0.000, 0.903)] significantly increased the likelihood of central hypoventilation. Conclusion: Disturbances in consciousness and elevated CSF antibody titers are risk factors for central hypoventilation in patients with anti-NMDAR encephalitis. It is imperative to closely monitor the respiratory status and oxygenation levels of patients identified as high-risk, conduct regular blood gas analyses, and implement respiratory support and more aggressive immunotherapy when necessary.

15 May 2026 in Medicine
Verified
Journal Article
Open access
RGRui Gao
Rui Gao
YHYan Hong
Yan Hong
GZGuanen Zhou
Guanen Zhou
Rationale: Anti leucine rich glioma inactivated 1 (LGI1)- associated autoimmune encephalitis (AE) is the common form of AE, The treatments for AE may cause many adverse effects and some treatments rely on limited blood resources. Monoclonal antibodies directed against neonatal crystallizable fragment receptor (FcRn), efgartigimod, accelerate autoantibody degradation by blocking IgG recirculation. The efficacy of efgartigimod has been demonstrated in myasthenia gravis. However, there are few case reports on the treatment of anti-LGI1-associated AE with efgartigimod. In this study, we present the case of a patient with anti-LGI1-associated AE who was treated with efgartigimod successfully. Patient concerns: A 64-year-old female patient presented with decline in short-term memory and limb tremor. Cranial magnetic resonance imaging (MRI) scan showed hyperintensity and swelling in the medial aspect of the right temporal-occipital lobe on T2- and FLAIR-weighted sequences, without obvious enhancement lesions. The anti-LGI1 antibody titer in serum and CSF was positive. Diagnoses: The patient was diagnosed with anti-LGI1-associated AE. Interventions: Initially, the patient received methylprednisolone pulse therapy. Levetiracetam and oxcarbazepine were both administered orally in the meantime. Following treatment failure, efgartigimod was administered once a week for 3 weeks. Outcomes: After treatment, the patient’s limb tremors ceased and her memory improved. The level of anti-LGI1 antibody titer in serum decreased, and the abnormal signals on the MRI attenuated. Lessons: Efgartigimod is an effective treatment for anti-LGI1-associated AE. This study presents a new approach to treat anti-LGI1-associated AE. However, further research is needed to establish the optimal dosage and frequency of efgartigimod, and to clarify its long-term safety and efficacy.

10 March 2021 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
XZXuan Zou
Xuan Zou
WZWenjuan Zhao
Wenjuan Zhao
MKMengdan Kong
Mengdan Kong
QLQian Liu
Qian Liu
LLLeilei Luo
Leilei Luo
GZGuanen Zhou
Guanen Zhou